IBM and IBM have joined forces to use blockchain recordkeeping in a clinical trial in China , using Boehringer ’s technology. They say they want to check whether a decentralised service can provide integrity and transparency in data, automate some processes and cut costs. The companies also want to make it easier for people taking part in trials to have control over their data. “We want to understand the value proposition of blockchain technology, and how that value would generally be applicable to many disease areas,” Brödl said. The trial will compare the system’s performance with established methods. Boehringer Ingelheim is already developing blockchain for its supply operations but the project with IBM will be its first use of blockchain in clinical research.
IBM and IBM have joined forces to use blockchain recordkeeping in a clinical trial in China , using Boehringer ’s technology. They say they want to check whether a decentralised service can provide integrity and transparency in data, automate some processes and cut costs. The companies also want to make it easier for people taking part in trials to have control over their data. The trial will compare the system’s performance with established methods. Boehringer Ingelheim is already developing blockchain for its supply operations but the project with IBM will be its first use of blockchain in clinical research.